Glaxosmithkline PLC

This profile gathers the share dealings of Glaxosmithkline PLC across 30 companies, led by Innoviva, Inc., Applied Genetic Technologies Corp and Quest Diagnostics Inc. Over a trading history stretching from 29 October 2007 to 2 July 2021, the count stands at 134 filings.

Both buying and selling appear: 52 purchases worth €1.4B, against 24 sales worth €2.0B. No amount is published for 2 filings, which the totals therefore leave out. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. In 2021 alone, the filings show 2 purchases and 1 sale.

Half of the purchases are above €4.5M and half below. On 14 out of 15 purchases, another insider of the same company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

The record was last updated on 6 July 2021 with a transaction in CVRx, Inc. The latest purchase dates back some time: it was published 1,936 days ago, on 6 July 2021. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.